Expert Financial Analysis and Reporting

Northwest issued a press release announcing a presentation at ASCO today by the Company’s Chief Technical Officer, Dr. Marnix Bosch. The Company said that it will issue updates on:

• The Phase 3 trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM) brain cancer,
• the Information Arm related to the phase 3 trial
• and the Company’s Phase I/II Trial of DCVax-Direct for inoperable solid tumors.

The presentation will be webcast live at: https://www.nwbio.com/dcvax-novel-personalized-immune-therapies-solid-tumors/ at 4:00 PM EST.

The phase 3 trial has not yet reached the needed 233 events (deaths) after which the data base will be locked and analyze. The trial remains blinded so there can be no information on the results of the trial. Perhaps, the Company can release unblinded data that might give some insight into the conduct of the trial. I am curious to hear what they have to say.

The information arm is unblinded so we could hear some information on progression free survival and overall survival. See this link for some background

We have not had an update on the phase 1.2 trial of DCVax-Direct since October 2016. See the link below for more background. It will be interesting to see what new information is presented.

Northwest Biotherapeutics: Recent Data Update on Phase 1/2 Trial of DCVax Direct is Encouraging (NWBO, Speculative Buy, $0.43)